Analysts' Top 5 Price Targets of March 25, 2025
Reading Time: 2 minutes
Crinetics Pharmaceuticals [US22663K1079]: Stifel initiates coverage with a Buy recommendation and a price target of $60 (65% upside potential) Stifel analyst Alex Thompson views Crinetics as a well-capitalized endocrinology company with several products nearing their first approvals. Notably, Paltusotin, a drug for the treatment of acromegaly and carcinoid syndrome, is seen as a potential game-changer. The expert estimates that Paltusotin could achieve a combined global peak sales of $2 billion. Pagaya Technologies [IL0011858912]: JMP Securities...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
